Results 121 to 130 of about 20,159 (186)

Prediction of cognitive outcome and progression to dementia using ω6-PUFA/ω3-PUFA ratio. [PDF]

Alzheimers Dement
Andrade V, Kleineidam L, Wagner-Thelen H, Ballarini T, Campos-Martin R, Martino-Adami P, Tripathi KP, Guyonnet S, Vellas B, Scherer M, Maier W, Pentzek M, Schmid M, Riedel-Heller S, Weyerer S, Bickel H, Wiese B, Egert S, Wagner M, Ramírez A.   +19 more
europepmc   +1 more source

Composite grey matter fingerprints for genetic frontotemporal dementia. [PDF]

J Neurol Neurosurg Psychiatry
Bouzigues A, Campana G, Joulot M, Gensollen N, Russell LL, Foster PH, Ferry-Bolder E, Van Swieten JC, Jiskoot LC, Seelaar H, Sánchez-Valle R, Laforce R, Graff C, Galimberti D, Vandenberghe R, de Mendonca A, Tiraboschi P, Santana I, Gerhard A, Levin J, Sorbi S, Otto M, Bertoux M, Lebouvier T, Ducharme S, Butler C, Finger E, Tartaglia MC, Masellis M, Rowe JB, Synofzik M, Moreno F, Borroni B, Leber I, Zanusso G, Rohrer JD, Migliaccio R, GENetic Frontotemporal dementia Initiative (GENFI).   +37 more
europepmc   +1 more source

Early onset rapidly progressive frontotemporal dementia due to a novel MAPT P301A variant with functional validation of pathogenicity. [PDF]

NPJ Dement
Hua K, Pearson MR, Apresa BI, Chung JM, Ambrose AJ, Hiatt SM, Lario Lago A, Hall MG, Rabkina L, Kwan S, Do J, Daghlas I, McDonough A, Guterman EL, Xu DJ, Rosen HJ, Grimwood J, Cochran JN, Arkin MR, Boxer AL, Yokoyama JS, Ljubenkov PA, Holmes BB.   +22 more
europepmc   +1 more source

A pathogenic Tau mutation drives autophagy-lysosome dysfunction that limits Tau degradation in a model of frontotemporal dementia. [PDF]

Nat Commun
Mirfakhar FS, Marsh JA, Sato C, Schache KJ, Minaya MA, Dolle RE, Pak SC, Silverman GA, Perlmutter DH, Macauley SL, Karch CM.   +10 more
europepmc   +1 more source

RNA-based therapeutics for Alzheimer's disease and related tauopathies: challenges and opportunities. [PDF]

J Prev Alzheimers Dis
Rajbanshi B, Brentari I, Denti MA, Cummings JL, Guruacharya A.   +4 more
europepmc   +1 more source

Regulation of Tau Alternative Splicing: A Novel Role for the Ribonucleoprotein RBM20. [PDF]

Int J Mol Sci
Corsi A, Valentino A, Bruno MG, Menichetti G, Belpinati F, Pereira MP, Valenti MT, Ruggiero A, Trabetti E, Bombieri C, Romanelli MG.   +10 more
europepmc   +1 more source

NDST3 suppression restores lysosomal acidification and ameliorates amyloid-β and MAPT/tau pathology in Alzheimer's disease. [PDF]

Transl Neurodegener
Ge C, Wang K, Tang H, Ke Y, Wang H, Fu Q, Xiu Y, Guo Y, Jia YF, Long Z, He G, Tang Q.   +11 more
europepmc   +1 more source

APOE*4 risk-modifying genes and drug targets in Alzheimer's disease through cell-type-specific genomic analyses. [PDF]

Alzheimers Dement
Zeng Y, Cook N, Yang C, Sivasankaran SK, Fujita M, Gardell ZA, Le Guen Y, Shigemizu D, Ozaki K, Morizono T, Hara N, Miyashita A, Ikeuchi T, Pottier C, Cruchaga C, Napolioni V, Corces MR, Menon V, Greicius MD, Belloy ME.   +19 more
europepmc   +1 more source

Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle^TM variants. [PDF]

MAbs
Sela T, Wirth T, Sommer A, Larraillet V, Butzer J, Lohmann S, Wittmann P, Klein C, Knoetgen H, Villasenor R, Indlekofer A, Hofer K, Schumacher F, Niewöhner J.   +13 more
europepmc   +1 more source

circPDE4B downregulation triggers GEMIN5‑dependent translational stress response and autophagy to reduce MAPT pathology. [PDF]

Alzheimers Dement
Puri S, van der Spek SJF, Lin M, Wang Z, Porter J, Hu J, Hu L, Rondón-Ortiz AN, Knyshov A, Libera JL, Counts SE, Lahiri DK, Tcw J, Emili A, Zhang X, Wolozin B.   +15 more
europepmc   +1 more source